Published in Circulation on December 21, 2009
Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J (2011) 3.00
Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J Clin Invest (2011) 2.37
Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial. Eur Heart J (2012) 1.91
High-density lipoprotein function, dysfunction, and reverse cholesterol transport. Arterioscler Thromb Vasc Biol (2012) 1.70
Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey. Drug Des Devel Ther (2011) 1.68
Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength? World J Diabetes (2014) 1.44
log(TG)/HDL-C is related to both residual cardiometabolic risk and β-cell function loss in type 2 diabetes males. Cardiovasc Diabetol (2010) 1.35
Cardioprotective functions of HDLs. J Lipid Res (2013) 1.29
Molecular mechanisms of vascular effects of High-density lipoprotein: alterations in cardiovascular disease. EMBO Mol Med (2012) 1.26
Critical role of the nitric oxide/reactive oxygen species balance in endothelial progenitor dysfunction. Antioxid Redox Signal (2010) 1.22
Unraveling the complexities of the HDL lipidome. J Lipid Res (2013) 1.19
Novel biological functions of high-density lipoprotein cholesterol. Circ Res (2012) 1.19
Scavenger receptor class B type I is a plasma membrane cholesterol sensor. Circ Res (2012) 1.13
Dysfunctional HDL and atherosclerotic cardiovascular disease. Nat Rev Cardiol (2015) 1.11
New insights into the mechanism of low high-density lipoprotein cholesterol in obesity. Lipids Health Dis (2011) 1.10
High density lipoproteins and endothelial functions: mechanistic insights and alterations in cardiovascular disease. J Lipid Res (2013) 1.09
Cardiovascular disease risk reduction by raising HDL cholesterol--current therapies and future opportunities. Br J Pharmacol (2012) 1.07
Lipidomics: a tool for studies of atherosclerosis. Curr Atheroscler Rep (2010) 1.02
The atherogenic dyslipidemia ratio [log(TG)/HDL-C] is associated with residual vascular risk, beta-cell function loss and microangiopathy in type 2 diabetes females. Lipids Health Dis (2012) 1.01
HDL cholesterol is not associated with lower mortality in patients with kidney dysfunction. J Am Soc Nephrol (2014) 1.01
HDL and endothelial protection. Br J Pharmacol (2013) 0.99
Pleiotropic effects of pitavastatin. Br J Clin Pharmacol (2012) 0.99
Regulation of signal transduction by HDL. J Lipid Res (2013) 0.97
Pathophysiology of diabetic dyslipidaemia: where are we? Diabetologia (2015) 0.96
Myeloperoxidase, inflammation, and dysfunctional high-density lipoprotein. J Clin Lipidol (2010) 0.94
Diabetic HDL is dysfunctional in stimulating endothelial cell migration and proliferation due to down regulation of SR-BI expression. PLoS One (2012) 0.93
HDL in children with CKD promotes endothelial dysfunction and an abnormal vascular phenotype. J Am Soc Nephrol (2014) 0.90
High density lipoprotein: a therapeutic target in type 2 diabetes. Endocrinol Metab (Seoul) (2013) 0.87
Niacin in cardiovascular disease: recent preclinical and clinical developments. Arterioscler Thromb Vasc Biol (2011) 0.87
HDL, Atherosclerosis, and Emerging Therapies. Cholesterol (2013) 0.87
Myeloperoxidase levels predict accelerated progression of coronary atherosclerosis in diabetic patients: insights from intravascular ultrasound. Atherosclerosis (2013) 0.86
HDL-apoA-I exchange: rapid detection and association with atherosclerosis. PLoS One (2013) 0.86
Effects of triple antioxidant therapy on measures of cardiovascular autonomic neuropathy and on myocardial blood flow in type 1 diabetes: a randomised controlled trial. Diabetologia (2013) 0.86
The causes and consequences of low levels of high density lipoproteins in patients with diabetes. Diabetes Metab J (2011) 0.86
Relationship between cardio-ankle vascular index and plasma lipids in hypertension subjects. J Hum Hypertens (2014) 0.86
Intravenously injected human apolipoprotein A-I rapidly enters the central nervous system via the choroid plexus. J Am Heart Assoc (2014) 0.84
Serum lipids, apolipoproteins, and mortality among coronary artery disease patients. Biomed Res Int (2014) 0.83
High density lipoprotein and cardiovascular diseases. World J Cardiol (2013) 0.81
Vascular endothelial function and oxidative stress are related to dietary niacin intake among healthy middle-aged and older adults. J Appl Physiol (1985) (2013) 0.81
The biphasic effects of oxidized-low density lipoprotein on the vasculogenic function of endothelial progenitor cells. PLoS One (2015) 0.80
Weight and inflammation are the major determinants of vascular dysfunction in the aortae of db/db mice. Naunyn Schmiedebergs Arch Pharmacol (2011) 0.80
High density lipoproteins: Measurement techniques and potential biomarkers of cardiovascular risk. BBA Clin (2015) 0.79
Anti-TNFα therapy transiently improves high density lipoprotein cholesterol levels and microvascular endothelial function in patients with rheumatoid arthritis: a pilot study. BMC Musculoskelet Disord (2012) 0.79
Low density lipoprotein cholesterol level inversely correlated with coronary flow velocity reserve in patients with Type 2 diabetes. J Geriatr Cardiol (2013) 0.79
Impaired High-Density Lipoprotein Anti-Oxidant Function Predicts Poor Outcome in Critically Ill Patients. PLoS One (2016) 0.78
Statins, HMG-CoA Reductase Inhibitors, Improve Neovascularization by Increasing the Expression Density of CXCR4 in Endothelial Progenitor Cells. PLoS One (2015) 0.78
4th Annual Symposium on Self Monitoring of Blood Glucose (SMBG) Applications and Beyond, May 12-14, 2011, Budapest, Hungary. Diabetes Technol Ther (2011) 0.78
Dysfunctional High-Density Lipoprotein: An Innovative Target for Proteomics and Lipidomics. Cholesterol (2015) 0.77
Add-on-Statin Extended Release Nicotinic Acid/Laropiprant but Not the Switch to High-Dose Rosuvastatin Lowers Blood Pressure: An Open-Label Randomized Study. Int J Hypertens (2011) 0.77
Glycoxidized HDL, HDL enriched with oxidized phospholipids and HDL from diabetic patients inhibit platelet function. J Clin Endocrinol Metab (2015) 0.77
Structural Insights into High Density Lipoprotein: Old Models and New Facts. Front Pharmacol (2016) 0.77
Oxidized high-density lipoprotein impairs endothelial progenitor cells' function by activation of CD36-MAPK-TSP-1 pathways. Antioxid Redox Signal (2014) 0.76
Extended-release niacin/laropiprant improves endothelial function in patients after myocardial infarction. Heart Vessels (2013) 0.76
[Clinical importance of HDL cholesterol]. Herz (2016) 0.76
Correlation between serum free fatty acids levels and Gensini score in elderly patients with coronary heart disease. J Geriatr Cardiol (2014) 0.75
Treatment with the herbal medicine, naoxintong improves the protective effect of high‑density lipoproteins on endothelial function in patients with type 2 diabetes. Mol Med Rep (2016) 0.75
Beneficial Effects of Reconstituted High-Density Lipoprotein (rHDL) on Circulating CD34+ Cells in Patients after an Acute Coronary Syndrome. PLoS One (2017) 0.75
Advances in the Study of the Antiatherogenic Function and Novel Therapies for HDL. Int J Mol Sci (2015) 0.75
Impact of low high-density lipoprotein-cholesterol level on 2-year clinical outcomes after acute myocardial infarction in patients with diabetes mellitus. Lipids Health Dis (2016) 0.75
High-density lipoprotein cholesterol as a predictor of poor survival in patients with nasopharyngeal carcinoma. Oncotarget (2016) 0.75
Impact of Lifestyle Intervention on HDL-Induced eNOS Activation and Cholesterol Efflux Capacity in Obese Adolescent. Cardiol Res Pract (2016) 0.75
Depletion in LpA-I:A-II particles enhances HDL-mediated endothelial protection in familial LCAT deficiency. J Lipid Res (2017) 0.75
Tachometer for reverse cholesterol transport? J Am Heart Assoc (2012) 0.75
High-density lipoprotein cholesterol (HDL-C) in cardiovascular disease: effect of exercise training. Integr Med Res (2016) 0.75
HDL in diabetic nephropathy has less effect in endothelial repairing than diabetes without complications. Lipids Health Dis (2016) 0.75
Citrulline increases cholesterol efflux from macrophages in vitro and ex vivo via ATP-binding cassette transporters. J Clin Biochem Nutr (2014) 0.75
The anti-inflammatory function of HDL is impaired in type 2 diabetes: role of hyperglycemia, paraoxonase-1 and low grade inflammation. Cardiovasc Diabetol (2017) 0.75
Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol (2002) 16.25
Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet (2004) 9.35
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation (2003) 8.61
Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J (2005) 7.75
Catheter-based renal nerve ablation and centrally generated sympathetic activity in difficult-to-control hypertensive patients: prospective case series. Hypertension (2012) 6.70
Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months' follow-up data from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST-elevation infarct regeneration) trial. Circulation (2006) 5.99
A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell (2007) 5.85
Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med (2009) 5.34
Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet (2009) 5.23
Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens (2009) 4.87
EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J (2006) 4.57
The renal arterial resistance index and renal allograft survival. N Engl J Med (2003) 4.36
Monitoring of bone marrow cell homing into the infarcted human myocardium. Circulation (2005) 4.20
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation (2003) 3.94
New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation (2003) 3.79
Role of oxidative stress in atherosclerosis. Am J Cardiol (2003) 3.66
Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation (2002) 3.65
Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome. Circulation (2007) 3.62
Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J (2005) 3.50
Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol (2002) 3.49
Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation (2004) 3.30
Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. Nat Genet (2012) 3.04
Heavy metal--rely on gut feelings: novel diagnostic approach to test drug compliance in patients with lanthanum intake. Nephrol Dial Transplant (2007) 2.96
The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury. Circ Res (2006) 2.85
Wegener's granulomatosis. Lancet (2006) 2.83
Clinical applications of stem cells for the heart. Circ Res (2005) 2.78
Comparable increase of B-type natriuretic peptide and amino-terminal pro-B-type natriuretic peptide levels in patients with severe sepsis, septic shock, and acute heart failure. Crit Care Med (2006) 2.77
Abnormal high-density lipoprotein induces endothelial dysfunction via activation of Toll-like receptor-2. Immunity (2013) 2.74
Endothelial function: a critical determinant in atherosclerosis? Circulation (2004) 2.71
Pathogenesis and management of hypertension after kidney transplantation. J Hypertens (2011) 2.66
Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis. BMJ (2014) 2.62
Immunosuppressive treatment protects against angiotensin II-induced renal damage. Am J Pathol (2002) 2.50
Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation (2005) 2.49
Prospective biopsy-controlled evaluation of cell death biomarkers for prediction of liver fibrosis and nonalcoholic steatohepatitis. Hepatology (2011) 2.49
Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J Am Coll Cardiol (2007) 2.46
Signal transducer and activator of transcription 3 is required for myocardial capillary growth, control of interstitial matrix deposition, and heart protection from ischemic injury. Circ Res (2004) 2.45
Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension (2010) 2.38
Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J Clin Invest (2011) 2.37
Evaluation of postnatal arteriogenesis and angiogenesis in a mouse model of hind-limb ischemia. Nat Protoc (2009) 2.34
Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. BMJ (2012) 2.32
Circulating miR-210 predicts survival in critically ill patients with acute kidney injury. Clin J Am Soc Nephrol (2011) 2.27
Etiology, management, and outcome of the Budd-Chiari syndrome. Ann Intern Med (2009) 2.26
Androgens and coronary artery disease. Endocr Rev (2003) 2.26
Prospective assessment of risk factors for recurrent stroke during childhood--a 5-year follow-up study. Lancet (2002) 2.25
Erythropoietin regulates endothelial progenitor cells. Blood (2003) 2.18
AT1 receptor agonistic antibodies from preeclamptic patients stimulate NADPH oxidase. Circulation (2003) 2.15
Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation (2003) 2.12
Altered activation of endothelial anti- and proapoptotic pathways by high-density lipoprotein from patients with coronary artery disease: role of high-density lipoprotein-proteome remodeling. Circulation (2013) 2.11
Oral L-serine supplementation reduces production of neurotoxic deoxysphingolipids in mice and humans with hereditary sensory autonomic neuropathy type 1. J Clin Invest (2011) 2.08
Stimulation of endothelial progenitor cells: a new putative therapeutic effect of angiotensin II receptor antagonists. Hypertension (2005) 2.01
Circulating endothelial cells as markers for ANCA-associated small-vessel vasculitis. Lancet (2003) 2.00
Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol (2005) 2.00
Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Press (2009) 1.98
Angiotensin II induces endothelial xanthine oxidase activation: role for endothelial dysfunction in patients with coronary disease. Arterioscler Thromb Vasc Biol (2007) 1.97
Increased hepatotoxicity of tumor necrosis factor-related apoptosis-inducing ligand in diseased human liver. Hepatology (2007) 1.97
Serum creatinine, cystatin C, and beta-trace protein in diagnostic staging and predicting progression of primary nondiabetic chronic kidney disease. Clin Chem (2010) 1.95
Renal cell carcinoma in transplant recipients with acquired cystic kidney disease. Clin J Am Soc Nephrol (2007) 1.95
Excess circulating angiopoietin-2 is a strong predictor of mortality in critically ill medical patients. Crit Care (2008) 1.94
Hereditary sensory neuropathy type 1 is caused by the accumulation of two neurotoxic sphingolipids. J Biol Chem (2010) 1.93
Inhibition of calcineurin-NFAT hypertrophy signaling by cGMP-dependent protein kinase type I in cardiac myocytes. Proc Natl Acad Sci U S A (2002) 1.88
Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: role of xanthine-oxidase and extracellular superoxide dismutase. Circulation (2002) 1.87
HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis (2002) 1.87
The Hannover Dialysis Outcome study: comparison of standard versus intensified extended dialysis for treatment of patients with acute kidney injury in the intensive care unit. Nephrol Dial Transplant (2009) 1.86